Inquiry Basket
Loading ......
The dynamic balance between oncogene and tumor suppressor protein activity constitutes the fundamental regulatory network of cellular homeostasis, and its disruption drives tumorigenesis and cancer progression. Cancer proteins are usually caused by mutations, amplification, or dysregulation of oncogenes, acting as constitutive activity signals to promote uncontrolled cell growth, proliferation, and survival. Examples worth noting include Ras, MYC, and ERBB2, which, when abnormally activated, drive downstream signaling pathways favorable for tumor transformation. In contrast, tumor suppressor proteins such as p53, Rb, and BRCA1 act as key barriers against malignant transformation by regulating cell cycle checkpoints, initiating cell apoptosis, and maintaining genomic integrity. The quantitative analysis of these key proteins provides valuable insights into cancer biology and contributes to the development of targeted therapies.
Figure 1. Oncogene.
The strategic implementation of validated ELISA kits for oncogene and tumor suppressor protein analysis provides an indispensable platform for advancing cancer drug development plans. As demonstrated by examining case studies of NOV and OSM, these robust quantitative analyses provide key insights into potential biomarkers for drug action mechanisms, resistance pathways, and patient stratification. The continuous development of ELISA technology, including enhanced sensitivity, multiplexing capabilities, and automated platforms, is expected to further expand its utility throughout the entire treatment development process. By integrating these precise protein quantification tools into a comprehensive research and development workflow, scientists can accelerate the translation of fundamental discoveries in cancer biology into effective targeted therapies for cancer patients.
Figure 2. Structure of Oncogene.
The implementation of the oncogene and tumor suppressor protein ELISA kit covers the entire drug development process from early detection to clinical development. These detections accelerate the identification and characterization of promising therapeutic candidates at each stage of strategic application, while reducing the risk of developing pipelines. ELISA kits promote target validation by quantifying the expression of oncogenes and tumor suppressor proteins in cancer cell lines and patient derived tissues, thereby establishing a convincing correlation between target dysregulation and disease pathology. During the lead optimization process, these detections can high-throughput screen compound libraries and identify candidates that effectively regulate the expression or activity of target proteins.
Table 1: Applications of Oncogene and Tumor Suppressor ELISA Kits in Drug Development
| Development Stage | Primary Application | Key Information Gained |
| Target Validation | Confirm protein dysregulation in disease states | Expression correlation with cancer subtypes and progression |
| Lead Optimization | High-throughput screening of compound libraries | Structure-activity relationships based on target modulation |
| Preclinical | Pharmacodynamic biomarker assessment | Proof of mechanism, dose-response relationships, PK/PD modeling |
| Clinical Development | Patient stratification and therapy monitoring | Identification of likely responders, assessment of target engagement in humans |
High sensitivity
Low detection limit, can be quantified in serum/plasma with typically low protein levels. It can solve the problem of low target protein content in serum and other samples.
High Specificity
By designing specific antibodies and conducting rigorous cross reaction validation, we ensure that the detection results only target the target protein.
Specificity
Minimal cross-reactivity with related proteins (e.g., OSM kit shows<1% cross-reactivity with IL-6) ensures accurate target measurement.
Flexibility
Validated for diverse sample types (serum, cell supernatants, tissue lysates) used in both preclinical (xenografts) and clinical (patient samples) research.
ELISA kits play a crucial role in cancer research and drug development, enabling precise quantitative analysis of oncogenes and tumor suppressor proteins. These detection tools are widely used in various fields such as target validation, drug screening, mechanism research, and biomarker development. By accurately quantifying the expression levels of these key regulatory proteins, researchers can gain a deeper understanding of the molecular mechanisms underlying tumor development, evaluate drug efficacy, and promote the development of precision medicine. The following is a summary of the core information of our featured products corresponding to ELISA kits.
| Product Name | Target Name | Gene Type | Main Function | Sample Type | Main Application Fields |
| MYC ELISA Kit | MYC | Oncogene | Transcription factor regulating cell proliferation, metabolism, and apoptosis | Serum | Tumor mechanism research, cancer prognosis evaluation, drug target screening |
| MYB ELISA Kit | MYB | Oncogene | Transcription factor regulating hematopoiesis and cell cycle | Serum, plasma, cell culture supernatant | Leukemia research, tumor proliferation mechanism analysis, anticancer drug screening |
| MN1 ELISA Kit | MN1 | Oncogene | Transcriptional coactivator associated with hematologic tumors | Serum, plasma, related biological fluids | Meningioma research, acute myeloid leukemia prognosis, gene expression regulation |
| CBL ELISA Kit | CBL | Tumor Suppressor Gene | E3 ubiquitin ligase, negatively regulating receptor tyrosine kinases | Cells | Signal transduction research, immune regulation analysis, tumor suppression mechanisms |
| Rat Beclin-1 (BECN1) ELISA Kit | Beclin-1 | Tumor Suppressor Gene | Key autophagy regulatory protein, maintaining cellular homeostasis | Serum, plasma, tissue homogenate, cell culture supernatant | Autophagy research, tumor suppression mechanisms, neurodegenerative disease studies |
Case Study 1: Human NOV ELISA Development Kit in Oncogenic Mechanism Analysis
Case Study 2: Human OSM ELISA Kit in Tumor Suppressor Response Monitoring
We collect and process clinical samples (serum/plasma) to eliminate hemolysis/hyperlipidemia and ensure compliance with pre analytical quality standards prior to testing.
We initialize the ELISA kit by preparing calibration samples constructed from standard curves and running low/high concentration quality control materials.
We add the processed sample to a pre coated microplate, incubate to form a sandwich complex, and perform sequential washing to remove non-specific binding.
We measured absorbance using a microplate reader, and calculated tumor marker concentrations using a validated regression model.
We cross validate the results based on the quality control scope, address potential interferences (such as hook effects), and generate clinically actionable reports.
The strategic implementation of validated ELISA kits for oncogene and tumor suppressor protein analysis provides an indispensable platform for advancing cancer drug development plans. As demonstrated by examining case studies of NOV and OSM, these robust quantitative analyses provide key insights into potential biomarkers for drug action mechanisms, resistance pathways, and patient stratification. The continuous development of ELISA technology, including enhanced sensitivity, multiplexing capabilities, and automated platforms, is expected to further expand its utility throughout the entire treatment development process. By integrating these precise protein quantification tools into a comprehensive research and development workflow, scientists can accelerate the translation of fundamental discoveries in cancer biology into effective targeted therapies for cancer patients.
Several technical and biological parameters should guide the selection of reagent kits, including the specificity of antibodies to expected targets, compatibility with sample matrices (serum, plasma, cell lysate, etc.), dynamic range relative to expected protein concentrations, and species reactivity requirements.
Standard ELISA kits typically detect total protein levels regardless of phosphorylation status, unless specifically designed for phosphate specific ELISA. These specialized reagent kits use capture antibodies to identify epitopes containing phosphorylated amino acid residues, enabling selective quantification of activated signaling molecules.
Sample integrity begins with appropriate collection conditions using approved anticoagulants (EDTA, citrate, or heparin for plasma), followed by rapid processing to isolate cellular components. For most analytes, it is recommended to rapidly freeze aliquots at -80 ° C to maintain stability and avoid repeated freeze-thaw cycles, which can reduce protein structure and function.
For cell lysate, BCA assay and other total protein quantification methods provide a practical standardized approach. For tissue homogenates, expression is usually normalized to total protein content or housekeeping protein when performing parallel Western blot analysis. When analyzing serum or plasma, some researchers standardize it as total serum protein, although this method may introduce variability; Therefore, reporting absolute concentration is usually the preferred method for circulating biomarkers.
Loading ......
